{name}
{subtitle}
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~77 mi. (Wrocław, Poland, +130 more cities)
facility
Uniwesytecki Szpital Kliniczny we Wroclawiu ( Site 0669)
drug
BCG solution, +1 more drug
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~77 mi. (Wrocław, Poland, +207 more cities)
facility
Dolnoslaskie Centrum Onkologii. ( Site 1820)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~77 mi. (Wrocław, Poland, +159 more cities)
facility
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1062)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~77 mi. (Wrocław, Poland, +163 more cities)
facility
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1063)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~77 mi. (Wrocław, Poland, +127 more cities)
facility
Dolnoslaskie Centrum Onkologii. ( Site 2507)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
city
~77 mi. (Wrocław, Poland, +72 more cities)
facility
Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku
biomarker
del(11)(q10), +27 more biomarkers
condition
Primary Myelofibrosis, +1 more condition